Login to Your Account



Targacept Slides on Unexpected Phase III Depression Failure

By Catherine Shaffer
BioWorld Today Contributing Writer

Wednesday, November 9, 2011
Stock in Targacept Inc. dropped 60.2 percent Tuesday on news that its Phase III RENAISSANCE trial of TC-5214 in depression failed to meet its primary endpoint of change on the Montgomery-Asberg Depression Rating Scale (MADRS) following eight weeks of treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription